ZYME
Zymeworks Inc.
Biotechnology · Healthcare · United States
25.76
close · 2026-08-13
value
22
cheaper than peers22
quality
6
stronger fundamentals6
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 21.89× | 47 |
| price to sales | 46.18× | 26 |
| price to book | 11.75× | 20 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 19.9% | 50 |
| return on equity | -72.3% | 24 |
| operating margin | -919.0% | 15 |
| revenue growth | -90.6% | 6 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | -$65.1M |
| employees | 231 |
| first trade | 2017-04-28 |
| next earnings | 2026-08-06 |
| fundamentals updated | 2026-08-10 |